These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 29504102)

  • 1. Role of Matrix Metalloproteinase-2 in the Development of Cyclophosphamide-Induced Cardiomyopathy.
    Koldysheva EV; Klinnikova MG; Nikityuk DB; Ivleva EK; Listvyagova NA; Lushnikova EL
    Bull Exp Biol Med; 2018 Mar; 164(4):483-487. PubMed ID: 29504102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury.
    Bil-Lula I; Lin HB; Biały D; Wawrzyńska M; Diebel L; Sawicka J; Woźniak M; Sawicki G
    J Cell Mol Med; 2016 Jun; 20(6):1086-94. PubMed ID: 26992120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to protect doxorubicin-induced cardiomyopathy in male albino rats?
    Shaker O; Sourour DA
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Flk-1 and Cyclin D2 mRNA in the Myocardium of Rats with Doxorubicin-Induced Cardiomyopathy and after Treatment with Betulonic Acid Amide.
    Mzhelskaya MM; Klinnikova MG; Koldysheva EV; Lushnikova EL
    Bull Exp Biol Med; 2017 Oct; 163(6):809-813. PubMed ID: 29063324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age.
    Antonov IB; Kozlov KL; Pal'tseva EM; Polyakova OV; Lin'kova NS
    Bull Exp Biol Med; 2018 Mar; 164(4):550-553. PubMed ID: 29504111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cardiac expression of two isoforms of matrix metalloproteinase-2 in experimental diabetes mellitus.
    Lee HW; Lee SJ; Lee MY; Park MW; Kim SS; Shin N; Lovett DH; Bae SS; Ahn J; Park JS; Oh JH; Choi JH; Lee HC; Cha KS; Hong TJ; Song SH
    PLoS One; 2019; 14(8):e0221798. PubMed ID: 31461499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective.
    Bencsik P; Pálóczi J; Kocsis GF; Pipis J; Belecz I; Varga ZV; Csonka C; Görbe A; Csont T; Ferdinandy P
    Pharmacol Res; 2014 Feb; 80():36-42. PubMed ID: 24380772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of trypsin-like enzymes and gelatinases in rats with doxorubicin cardiomyopathy.
    Gordiienko IuA; Babets YV; Kulinich AO; Shevtsova AI; Ushakova GO
    Ukr Biochem J; 2014; 86(6):139-46. PubMed ID: 25816614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
    Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
    J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy.
    Van Linthout S; Seeland U; Riad A; Eckhardt O; Hohl M; Dhayat N; Richter U; Fischer JW; Böhm M; Pauschinger M; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2008 Jul; 103(4):319-27. PubMed ID: 18347835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes.
    Fan X; Hughes BG; Ali MA; Chan BY; Launier K; Schulz R
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H183-9. PubMed ID: 27199120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructure and stereology of cardiomyocytes in the development of regenerative and plastic myocardial insufficiency during ontogeny.
    Nepomnyashchikh LM; Lushnikova EL; Molodykh NA; Klinnikova MG; Molodykh OP
    Bull Exp Biol Med; 2011 May; 151(1):88-94. PubMed ID: 22442810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice.
    Kizaki K; Ito R; Okada M; Yoshioka K; Uchide T; Temma K; Mutoh K; Uechi M; Hara Y
    Pharmacol Res; 2006 Apr; 53(4):341-6. PubMed ID: 16455267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Analysis of the Myocardium in Experimental Anthracycline-Induced Cardiomyopathy Combined with Adrenergic Stimulation.
    Lushnikova EL; Molodykh OP; Nikityuk DB; Semenov DE; Klinnikova MG
    Bull Exp Biol Med; 2019 Mar; 166(5):689-694. PubMed ID: 30903493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiomyocyte count in rat myocardium under the effect of antitumor agents cyclophosphamide and triterpenoids.
    Lushnikova EL; Tolstikova TG; Nepomnyashchikh LM; Klinnikova MG; Molodykh OP; Sviridov EA; Sorokina IV; Zhukova NA
    Bull Exp Biol Med; 2007 Sep; 144(3):355-61. PubMed ID: 18457036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression.
    Li HQ; Wu YB; Yin CS; Chen L; Zhang Q; Hu LQ
    Biomed Pharmacother; 2016 Jul; 81():474-481. PubMed ID: 27261628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy.
    Westermann D; Savvatis K; Lindner D; Zietsch C; Becher PM; Hammer E; Heimesaat MM; Bereswill S; Völker U; Escher F; Riad A; Plendl J; Klingel K; Poller W; Schultheiss HP; Tschöpe C
    Circulation; 2011 Nov; 124(19):2082-93. PubMed ID: 21986287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase 9/neutrophil gelatinase associated lipocalin/tissue inhibitor of metalloproteinasess type 1 complexes are localized within cardiomyocytes and serve as a reservoir of active metalloproteinase in porcine female myocardium.
    Kiczak L; Tomaszek A; Bania J; Paslawska U; Zacharski M; Janiszewski A; Rybinska I; Dziegiel P; von Haehling S; Ardehali H; Jankowska EA; Ponikowski P
    J Physiol Pharmacol; 2014 Jun; 65(3):365-75. PubMed ID: 24930508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of glutamine on matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-3 expressions in myocardium of rats with sepsis].
    Wang H; Yu XY; Sun M; Pan JK; Gao H
    Zhonghua Er Ke Za Zhi; 2006 Aug; 44(8):587-91. PubMed ID: 17083784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.